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 PIKfyve complex regulates early melanosome homeostasis 
required for physiological amyloid formation 
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Summary Statement 
In pigment cells, generation of PI(3,5)P2 by the PIKfyve complex regulates 
endosomal actin branching and associated membrane remodeling of early 
melanosomes. This process controls import-export balance that is required for 
functional amyloid formation and melanosome identity.  
Abstract 
The metabolism of PI(3,5)P2 is regulated by the PIKfyve, VAC14 and FIG4 complex, 
whose mutations are associated with hypopigmentation in mice. These pigmentation 
defects indicate a key but yet unexplored physiological relevance of this complex in 
the biogenesis of melanosomes. Here we show that PIKfyve activity regulates 
formation of amyloid matrix composed of PMEL protein within early endosomes, 
called stage I melanosomes. PIKfyve activity controls the membrane remodeling of 
stage I melanosomes that increases PMEL abundance and impairs its sorting and 
processing. PIKfyve activity also affects stage I melanosome kiss-and-run 
interactions with lysosomes that is required for PMEL amyloidogenesis and 
establishment of melanosome identity. Mechanistically, PIKfyve activity promotes the 
formation and membrane tubules from stage I melanosomes and their release by 
modulating endosomal actin branching. Together our data indicate that PIKfyve 
activity is a key regulator of the melanosomal import-export machinery that fine tunes 
the formation of functional amyloid fibrils in melanosomes and the maintenance of 
melanosome identity. 
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Introduction 
The protein complex composed of the kinase PIKfyve (Fab1), the phosphatase FIG4 
(Sac3) and the scaffolding protein VAC14 (ArPIKfyve) regulates levels of 
phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) (Ikonomov et al., 2009; Jin et al., 
2008) and PI(5)P in mammalian cells (Sbrissa et al., 2012; Zhang et al., 2007). 
These low abundant signaling lipids of endosomal membranes are key regulators in 
the homeostasis of the endolysosomal system (McCartney et al., 2014; Viaud et al., 
2014). Although FIG4 acts as a PI(3,5)P2 5-phosphatase (Duex et al., 2006a; Rudge 
et al., 2004), its activity is also required, together with VAC14, for activation of 
PIKfyve (Bonangelino et al., 2002; Dove et al., 2002; Duex et al., 2006b; Jin et al., 
2008). Thus, depletion not only of VAC14 and PIKfyve, but also of FIG4 reduces 
cellular PI(3,5)P2 levels  (Chow et al., 2007; Zhang et al., 2007; Zolov et al., 2012). 
Inhibition or depletion of the PIKfyve/VAC14/FIG4 complex (hereafter called PIKfyve 
complex) impairs endolysosomal functions such as endosome-to-TGN transport, 
endosomal homeostasis and autophagy (Ferguson et al., 2009; McCartney et al., 
2014). However, the molecular mechanisms by which the PIKfyve complex controls 
these processes and their physiological relevance remain to be fully understood. 
Mouse models with mutations in VAC14 or FIG4 exhibit diluted pigmentation (Chow 
et al., 2007; Jin et al., 2008; Zhang et al., 2007). This hypopigmentation suggests 
that in melanocytes the PIKfyve complex may be involved in the biogenesis of 
melanosomes, in which the pigment melanin is synthesized. Our current 
understanding of the stepwise process of melanosome biogenesis from endosomes 
provides a unique opportunity to investigate the molecular origin of hypopigmentation 
and the role of the PIKfyve complex in the endosomal system (Bissig et al., 2016; 
Sitaram and Marks, 2012).  
 
Melanogenesis involves two sequential but independent processes, functional 
amyloid fibril formation and pigment synthesis. Melanosomes are lysosome-related 
organelles that derive from early endosomes, which are called stage I melanosomes 
in pigment cells. During melanosome biogenesis, stage I melanosomes mature into 
stage II melanosomes which have acquired specific identity and morphology distinct 
from lysosomal organelles. Stage I melanosomes have been proposed to be the 
crossroad where melanosomal and endolysosomal pathways segregate (Raposo et 
al., 2001). However, the underlying molecular mechanisms of this segregation are 
	not fully understood. Stage I melanosomes are characterized by a clathrin coat and 
few intralumenal vesicles (ILVs) (Raposo et al., 2001). In their lumen amyloid fibril 
generation is initiated from cleavage products of PMEL, a transmembrane protein 
expressed in melanocytes (Bissig et al., 2016). During maturation into stage II 
melanosomes, the formation of these fibrils requires concomitant proteolytic 
processing of PMEL and differential sorting of PMEL cleavage products (Hurbain et 
al., 2008; Rochin et al., 2013; Theos et al., 2006b; van Niel et al., 2015; van Niel et 
al., 2011). PMEL amyloidogenesis is completed in ellipsoidal shaped stage II 
melanosomes where the assembled amyloid lumenal fibrils serve as a matrix for 
pigment deposition in later stage III and IV melanosomes, which have acquired 
melanogenic enzymes (Raposo et al., 2001). This matrix is proposed to sequester 
highly reactive oxidative intermediates of melanin production, which otherwise may 
oxidize melanosomal content and damage organelle integrity (Fowler et al., 2006; 
Lee et al., 1996).  
 
Here, we show that PIKfyve activity promotes the formation of membrane tubules 
emerging from stage I melanosomes and regulates their release by controlling 
branched actin dynamics. Interference with PIKfyve activity abrogates membrane 
tubule formation and branched actin-dependent release, which strongly affects stage 
I melanosomes homeostasis and leads to accumulation of unstructured aggregates 
of amyloidogenic PMEL fragments preventing amyloid matrix formation. These 
defects are accompanied by prolonged kiss-and-run interactions of stage I 
melanosomes with lysosomal compartments that affect melanosome identity and 
maturation. 
 
 
Results 
PIKfyve complex is required for PMEL fibril formation  
To gain insight into the pigmentation defect caused by loss of VAC14 and FIG4 we 
used conventional electron microscopy (EM) for morphological analysis of 
melanosomes in the retinal pigment epithelium (RPE) in eyes of newborn mutant 
mice (Chow et al., 2007; Zhang et al., 2007). These melanosomes are fully mature 
and less susceptible to compensatory effects, as they are formed during a brief 
developmental period (Lopes et al., 2007). Compared to wild type (WT) RPE, we 
found fewer but enlarged melanosomes per µm2 in the RPE of Fig4-/- and Vac14-/- 
mice (Figure 1A-D). Enlargment of melanosomes associated with hypopigmentation 
is reminiscent of those observed in ocular albinism type 1 (OA1)-deficient mice 
(Incerti et al., 2000), where the melanin-synthesizing enzyme tyrosinase-related 
protein 1 (TYRP1) is mistrafficked and LAMP-1, a lysosomal protein usually poorly 
present in early and late melanosomes (Raposo et al., 2001) (Figure S1 left panels), 
is enriched in these compartments. The melanosomes in the RPE of Fig4-/- and 
Vac14-/- mice were also rounder than in the elongated wildtype melanosomes 
(Figure 1E). As reported previously for melanosomes in the RPE of mouse mutants 
Bace2-/- (Rochin et al., 2013), PMEL silver (Dunn, 1930) and Pmel-/- (Hellstrom et al., 
2011), round melanosomes are indicative of a defect in PMEL fibril assembly, since 
the fibrils give melanosomes their characteristic ellipsoidal shape (Hellstrom et al., 
2011; Theos et al., 2006a). Vac14L156R/L156R and Fig4-/- mice also exhibit the diluted 
coat color characteristic of certain cases of impaired PMEL fibril assembly (Chow et 
al., 2007; Dunn, 1930; Hellstrom et al., 2011; Jin et al., 2008; Rochin et al., 2013; 
Zhang et al., 2007).  
To confirm these findings, we used human melanocytic cell line MNT-1 to knock 
down PIKfyve, VAC14 or FIG4 by RNAi (Figure 1F). In these knocked down cells 
(Figure 1G-H) and in MNT-1 cells treated with the PIKfyve inhibitor YM201636 
(Figure S1A-E), we found more lysosomal LAMP1 and PSEN2 localized to stage II 
melanosomes containing processed PMEL. We also observed miscolocalization of 
LAMP1 with the melanin-synthesizing protein TYRP1 present on pigmented 
melanosomes upon YM201636 treatment (Figure S1A-C). But the TYRP1 was 
correctly localized to pigmented melanosomes (Figure 1I) and the melanin content 
was unchanged (Figure 1J), excluding abnormal targeting of melanizing enzymes as 
in OA1 depleted MNT-1 cells (Giordano et al., 2009). As reported in MNT-1 cells 
	displaying a defect in PMEL fibril assembly (Rochin et al., 2013; van Niel et al., 
2011), immuno-labeling with an antibody recognizing PMEL fibrils (anti-HMB45) was 
decreased in cells treated with RNAi against the PIKfyve complex protein when 
compared to control cells (Figure 1K-L). These findings indicate that the PIKfyve 
complex is involved in processes regulating PMEL fibril formation during early 
melanogenesis, which impact melanosome identity and maturation, but not pigment 
synthesis occurring at later steps of melanosome maturation.  
 
Lumenal PMEL fragments accumulate upon interference with PIKfyve function 
Generation of PMEL fibrils requires stepwise processing of PMEL by a serie of 
proteases (Figure 2A). First, mature P2 form of PMEL is cleaved by proprotein 
convertase (PC) generating lumenal M-alpha and transmembrane M-beta fragment 
that remain linked by a disulfide bond (Berson et al., 2003; Leonhardt et al., 2011; 
Theos et al., 2006b). Then, M-beta fragment is processed by beta-site APP-cleaving 
enzyme 2 (BACE2) generating a membrane-associated C-terminal fragment (CTF) 
and releasing amyloidogenic M-alpha into the melanosome lumen (Rochin et al., 
2013). Unknown lysosomal proteases then further proteolytically process M-alpha 
into amyloidogenic peptides that finally assemble into fibrils (Ho et al., 2016; 
Kawaguchi et al., 2015; Leonhardt et al., 2013). Given the reported involvement of 
PIKfyve complex in endolysosome homeostasis (Bissig et al., 2017; Jefferies et al., 
2008), we studied whether PIKfyve inhibition or knockdown would affect PMEL 
processing.  
Using a set of antibodies that recognize distinct epitopes and processed fragments 
of PMEL (Figure 2B) we found that PIKfyve complex knockdown or inhibition for 2 h 
and 24 h did not affect PC- and BACE2-mediated PMEL cleavage producing M-
alpha, M-beta and CTF fragments, but caused an accumulation of the CTF (Figure 
2C and S1G) that is not part of PMEL fibrils and of M-alpha (Figure S1G). Due to 
their amyloidogenic nature, PMEL fibril associated fragments distribute to the Triton 
X-100 insoluble fraction in cell lysates (Berson et al., 2003; Leonhardt et al., 2013; 
Watt et al., 2009). In this fraction, we found accumulation of M-alpha, M-alphaN, M-
alphaC (Figure 2D and S1H). Treatment of MNT-1 cells for 2 h and 24 h with a mix 
of lysosomal protease inhibitors (100 µM leupeptin, 10 µM pepstatin A and 10 µM E-
64d) led to a similar accumulation CTF, M-alpha, M-alphaN and M-alphaC (Figure 
2E-F) but decreased generation of RPT and PKD fragments. These results confirm 
	that lysosomal proteases are required for PMEL processing (Ho et al., 2016; 
Kawaguchi et al., 2015; Leonhardt et al., 2013), and suggest that accumulation of 
processed and non-processed fragments of PMEL lumenal domain under PIKfyve 
inhibition may be caused by changes of lysosomal activity. 
 
Lysosomal activity is not affected upon inhibition of PIKfyve  
We assessed the lysosomal functions of melanocytes treated with YM201636. In 
these cells neither the number nor the size of LAMP1 compartments significantly 
changed upon inhibition of PIKfyve activity (Figure 3A-D). Using ratiometric 
fluorescence imaging we detected similar pH of endolysosomes in mock and 
YM201636 treated cells (4.4 ± 0.2 and 4.5 ± 0.2, respectively) (Figure S2A-B) in 
good agreement with previous reports (Bissig et al., 2017; Ho et al., 2015). 
Internalization of proteolytically dequenched DQ-BSA showed that treatment with 
PIKfyve inhibitor slightly increased proteolysis of endocytosed DQ-BSA, although the 
effect was not statistically significant (Figure S2C-D). The levels of mature cathepsin 
D (CatD) decreased and immature CatD accumulated upon treatment with lysosomal 
protease inhibitors, but not upon YM201636 treatment (Figure S2E), indicating that 
PIKfyve inhibition does not impair endolysosomal activity. To reinforce these results, 
we assessed steady-state levels of the melanocyte specific transmembrane protein 
MART1, which is ubiquitylated and degraded in lysosomes (Levy et al., 2005). 
PIKfyve inhibition, in contrast to inhibition of lysosomal proteases did not cause 
MART1 accumulation (Figure S2E). The trafficking of fluid phase marker 
(DextranAF647) (Figure S2F-G) or lysosomal transmembrane protein (PSEN2) 
(Figure S2H-I) to lysosomes was not affected upon YM201636 treatment, showing 
that PIKfyve inhibition neither affected transport of endocytosed cargo to 
endolysosomes nor trafficking of lysosomal resident proteins. This set of data shows 
that inhibition of PIKfyve does not impair lysosomal activity, excluding lysosomal 
dysfunction as a cause for accumulation of PMEL fragments. 
 
Lysosomal activity is delivered to melanosomes through kiss-and-run 
Others and our data show that lysosomal protease activity is required for PMEL 
processing and fibril formation in stage I melanosomes (Ho et al., 2016; Leonhardt et 
al., 2013). However, in melanocytes lysosomes and melanosomes co-exist as 
separate entities with distinct content and morphology (Raposo et al., 2001). In line 
	with this, immuno-labeling of M-alpha species revealed their accumulation in EEA1, 
but not LAMP1 labelled compartments at steady state and upon inhibition of PIKfyve 
activity (Figure 3A-B, E-F). We speculated that PMEL localized in stage I 
melanosomes may be processed by lysosomal proteases through transient 
interactions of stage I melanosomes and endolysosomes, which could be affected by 
YM201636 treatment. 
We tested this hypothesis by live-cell imaging of MNT-1 cells co-expressing LAMP1-
mRuby2 and the PI(3)P-binding protein 2xFYVE-GFP, as markers for 
endolysosomes and stage I melanosomes, respectively. We confirmed in fixed cells 
that 2xFYVE-GFP is found on stage I melanosomes, which correspond to early 
endosomes in pigment cells and contain mature PMEL and M-alpha (Figure S3A-B). 
In contrast, 2xFYVE-GFP did not co-localize with endolysosomes or with later stages 
melanosomes containing fully formed PMEL fibrils or melanin synthesizing enzymes 
or endolysosomes (Figure S3C-F). Our live-cell imaging revealed that in mock 
treated cells 2xFYVE-GFP and LAMP1-mRuby2 compartments transiently interact 
for on average 4.0 sec without undergoing complete compartment mixing (Figure 
3I,K and movie 1-2). To assess whether membrane fusion occurs, endolysosomes of 
2xFYVE-GFP expressing cells were loaded by pulse-chase with DextranAF555 and 
transfer of endolysosomal DextranAF555 to 2xFYVE-GFP compartments was 
monitored by live-cell microscopy. We found that endolysosomal DextranAF555 can 
be transferred to 2xFYVE-GFP compartments (Figure 3L-M and movie 3), showing 
that membrane fusion between the two compartments occurs. These findings 
support our hypothesis that the substrate PMEL, localized to stage I melanosomes is 
processed by lysosomal proteases through transient fusions of stage I melanosomes 
and endolysosomes. These interorganellar kiss-and-runs strengthen the role of 
stage I melanosomes as crossroad between melanosomal and endolysosomal 
pathways and provides mechanistic insights into the segregation of both pathways.  
In YM201636 treated cells, stage I melanosomes and endolysosomes transiently 
interacted. However, the time of contact doubled when compared to mock (10.0 sec 
vs 4.0 sec), but was restored upon YM201636 washout and re-synthesis of 
PI(3,5)P2/PI(5)P (Figure 3J-K and S3G and movies 4-7). Moreover, upon PIKfyve 
inhibition the two compartments still transiently fused, as illustrated by the transfer of 
endolysosomal DextranAF555 (Fig 3N-O and movie 8). 
These data show that accumulation of processed and unprocessed PMEL/M-alpha 
	species in stage I melanosomes upon PIKfyve inhibition did not result from impaired 
transient fusion between stage I melanosomes and endolysosomes. However, the 
prolonged duration of contact between stage I melanosomes and endolysosomes 
upon inhibition of PIKfyve activity may cause over time the observed mislocalization 
of endolysosomal proteins to melanosomes and loss of melanosome identity.  
 
PMEL fragments accumulate in enlarged EEA1 compartments  
The absence of defect of lysosomal activity and morphology upon inhibition of 
PIKfyve activity led us investigate potential defect of the EEA1 compartments where 
PMEL fragments accumulated upon treatment. Interestingly, immuno-labeling 
showed that EEA1-positive compartements that accumulated PMEL/M-alpha species 
following YM201636 treatment (Figure 3E-F) were enlarged and less numerous 
when compared to control (Figure 3G-H). In good agreement with this, after PIKfyve 
inhibition by YM201636 treatment we observed enlargement of 2xFYVE-GFP-
positive stage I melanosomes, but not LAMP1-mRuby2-positive endolysosomes in 
our live-cell imaging experiments (Figure 3J).  
It is thus conceivable that PIKfyve activity directly regulates stage I melanosome 
homeostasis explaining the lack of PMEL fibrillation when PIKfyve function is 
impaired. 
To better characterize the apparent defect in early melanosomes, we performed EM 
analysis of resin embedded and chemically fixed MNT-1 cells knocked down for 
PIKfyve, VAC14 or FIG4 by RNAi or treated with the PIKfyve inhibitor YM201636 
(Figure 4A-B). In MNT-1 cells, melanosome biogenesis occurs continuously. 
Therefore, all four melanosome maturation stages are present and can 
morphologically be distinguished by EM. We observed enlarged ILV containing stage 
I melanosomes decorated with a clathrin coat in inhibitor or RNAi treated cells 
(Figure 4A-B). Of note the mean size increase was only significant for YM201636 
treatment and PIKfyve knockdown (Figure 4C). Similarly, stage I melanosomes were 
enlarged in human primary melanocytes knocked down for VAC14, FIG4 and 
PIKfyve (Figure 4F). In addition, MNT-1 cells treated with RNAi for the PIKfyve 
complex proteins displayed fewer fibril-containing stage II melanosomes, but more 
unpigmented melanosomes with unstructured lumenal aggregates (Figure 4D-E), 
further confirming our findings that the PIKfyve complex is involved in PMEL fibril 
formation (Figure 1K-L). In line with our observations that the PIKfyve complex is not 
	involved in pigment synthesis (Figure 1I-J), interference with PIKfyve complex did 
not alter the number and morphology of pigmented melanosomes (Figure 4A-B and 
E). These morphological observations show that the PIKfyve complex is required for 
stage I melanosome homeostasis and PMEL fibril formation, which is initiated in 
these compartments.  
PMEL fibrillation results from concomitant processing and sorting of the 
amyloidogenic lumenal domain of PMEL to ILVs of stage I melanosomes (Hurbain et 
al., 2008; Rochin et al., 2013; Theos et al., 2006b; van Niel et al., 2015; van Niel et 
al., 2011). Ultrathin cryosections of MNT-1 cells confirmed the presence of ILV in 
stage I melanosomes labeled by anti-PMEL-N antibody (Figure 4G-H), indicating that 
PIKfyve activity is not critical for ILV formation. These data also revealed that upon 
PIKfyve inhibition mature PMEL/M-alpha is localized to enlarged clathrin-coat 
containing stage I melanosomes, where it was mostly found on the limiting 
membrane and to a lesser extent on ILVs (Figure 4G-H). However, a similar amount 
of gold labeling was found on ILVs between YM201636 treated and control condition 
(Figure 4I), suggesting that PMEL/M-alpha sorting to ILVs is not impaired. However, 
accumulation of this fragment on the limiting membrane may indicate a saturation of 
the sorting machinery.  
Altogether, our results suggest that upon interference with the PIKfyve complex 
lumenal PMEL fragments accumulate in enlarged stage I melanosomes causing 
unstructured PMEL aggregation preventing fibril formation and impairing 
melanosome maturation.   
 
PIKfyve activity promotes membrane remodeling 
Our observations show that upon PIKfyve inhibition the size of stage I melanosomes 
doubles, their number decreases and they accumulate PMEL fragments. A similar 
organelle enlargement induced by inhibition of PIKfyve activity was observed for 
endolysosomes in HeLa cells. In these cells PIKfyve activity was shown to control 
endolysosome homeostasis by promoting membrane remodeling (Bissig et al., 
2017). Thus, we hypothesized that PIKfyve exerts a similar function on stage I 
melanosomes and we studied stage I melanosome homeostasis and membrane 
dynamics by live-cell microscopy using 2xFYVE-GFP. In mock treated cells these 
compartments were highly dynamic and underwent frequent homotypic fusion and 
fission (Movie 9). Their shape was heterogeneous, and they were often tubulated 
	(Figure 5A-B). These features were lost upon inhibition of PIKfyve activity, where 
stage I melanosomes were fewer, enlarged, spherical and lacked membrane tubules 
(Figure 5A-D). In addition, the compartments were less dynamic as compared to 
control (Movie 10). Upon YM201636 washout and re-synthesis of PI(3,5)P2/PI(5)P 
membrane dynamics was restored and tubules and buds were formed and released 
resulting in recovery of compartment size and number (Figure 5A-D and movie 11). 
These findings indicate that PIKfyve activity promotes membrane remodeling of 
stage I melanosomes required to maintain compartment size, number and 
homeostasis during homotypic fusion-fission processes of stage I melanosomes.  
To confirm these findings, we performed electron microscopy analyses on high-
pressure frozen and freeze-substituted melanocytes, because this technique 
optimally preserves subtle membrane deformation such as membrane tubulations. In 
mock treated cells multivesicular stage I melanosomes often displayed tubules and 
beared a clathrin coat on their limiting membrane. In contrast after YM201636 
treatment these compartments lost their tubular appearance and were enlarged, but 
still displayed clathrin coats. Upon YM201636 washout the tubular feature was 
restored and dividing enlarged compartments were observed (Figure 5E-H), showing 
that PIKfyve activity is required for membrane remodeling on stage I melanosomes. 
We assessed the contribution of this membrane remodeling to PMEL accumulation 
by performing immunofluorescence microscopy. YM201636 induced accumulation of 
PMEL fragments in these enlarged EEA1-positive stage I melanosomes that were 
both rescued after drug washout and PI(3,5)P2/PI(5)P re-synthesis (Figure 5I-K). 
These findings confirm that PIKfyve activity controls stage I melanosome size, 
number and dynamics by regulating fission processes of stage I melanosomes. 
Interference with PIKfyve activity by inhibiting the homotypic fission induce the 
accumulation of PMEL fragments in fewer but larger stage I melanosomes that 
would contribute to the impaired PMEL fibrillation.  
 
PIKfyve activity controls endosomal branched actin required for tubule release  
To refine the mechanisms involved in the inhibition of PMEL fibrillation upon PIKfyve 
activity we explored the downstream and upstream pathways regulated by this 
complex such as the activation of mucolipin channels by PI(3,5)P2 (Dong et al., 
2010), PI(3)P levels (Zolov et al., 2012), pH (Jefferies et al., 2008) or endosomal 
actin branching (Hong et al., 2015). In MNT-1 cells, co-treatment of YM201636 with 
	the mucolipin activator MLSA1 did not restore stage I melanosome size and 
membrane dynamics (Figure S4A-B). These findings indicate that mucolipins may 
not be downstream effectors of PIKfyve activity in melanosome biogenesis, which is 
in line with our observations in HeLa cells (Bissig et al., 2017). Ratiometric 
fluorescence imaging with a short pulse-chase protocol excluded a pH defect in 
stage I melanosomes as a cause of impaired fibrillation of PMEL (Figure S4C). 
Inhibition of PIKfyve activity was shown to cause a slight increase in the PI(3,5)P2 
substrate PI(3)P in some, but not all cell types (Jefferies et al., 2008; Zolov et al., 
2012). Upon inhibition of PIKfyve activity we did not observe any change in the 
localization or intensity of fluorescence associated to endogenous protein EEA1 nor 
to 2xFYVE-GFP that both bind PI3P (Figure S4D). Similarly, biochemical analysis 
showed no significant differences in membrane recruitment of endogenous EEA1 
and expressed 2xFYVE-GFP between DMSO and YM201636 treated cells (Figure 
S4E-F). These results show that localization of PI(3)P-binding proteins is unaffected 
upon PIKfyve inhibition and indicate that in melanocytes PI(3)P does likely not 
accumulate upon PIKfyve activity inhibition.  
Recently, PI(3,5)P2 has been shown to control dynamics of branched actin on 
endosomal membranes (Hong et al., 2015), which is itself involved in various 
membrane remodeling processes (Anitei and Hoflack, 2011). Thus, we asked 
whether PIKfyve activity promotes membrane remodeling through regulation of 
endosomal actin dynamics. As observed in human breast adenocarcinoma cells 
(Hong et al., 2015), we found that actin patches accumulated on EEA1-positive and 
enlarged stage I melanosomes upon PIKfyve inhibitor treatment. Actin accumulation 
was abolished upon inhibition of the Arp2/3 complex by treatment with CK666 
(Figure 6A). These data reveal that in melanocytes as in other cells PI(3,5)P2/PI(5)P 
regulates branched endosomal actin. 
We performed live-cell imaging of 2xFYVE-GFP transfected cells to study whether 
endosomal actin is involved in PI(3,5)P2/PI(5)P-mediated membrane remodeling. 
Stage I melanosomes of cells treated with the Arp2/3 inhibitor CK666 still displayed 
membrane tubules. Similarly, when YM201636 was washed out in the presence of 
CK666, membrane tubules were observed (Figure 6B and 6C-E), showing that 
endosomal branched actin is not required for PI(3,5)P2/PI(5)P-mediated membrane 
remodeling. However, upon inhibition of branched actin dynamics by CK666 
treatment, membrane buds and tubules were less readily released and often 
	collapsed (Figure 6C-E and movie 12-15), suggesting that endosomal actin 
dynamics is involved in membrane tubule release.  
Electron microscopy analyses of high-pressure frozen MNT-1 cells confirmed that 
upon inhibition of Arp2/3 complex tubules are formed on stage I melanosomes 
(Figure 6F). Similarly, membrane tubules on enlarged stage I melanosomes were 
observed upon YM201636 washout in the presence of CK666 (Figure 6F), but stage 
I melanosomes were still enlarged after 4 h YM201636 washout in the presence of 
CK666, indicating that although membrane tubules are formed the compartment size 
was not rescued (Figure 6F), probably because the tubules were less readily 
released. Immunofluorescence microscopy showed that YM201636 induced 
accumulation of PMEL in EEA1-positive stage I melanosomes and their enlargement 
were rescued after drug washout and PI(3,5)P2/PI(5)P re-synthesis. However, both 
accumulation of PMEL and enlargement of EEA1-positive stage I melanosomes 
persisted when YM201636 was washed out in the presence of Arp2/3 complex 
inhibitor (Figure 6G-I), showing that PI(3,5)P2/PI(5)P-mediated membrane 
remodeling and endosomal actin dynamics are involved in the same pathway. Thus, 
our findings indicate that PI(3,5)P2/PI(5)P spatially and temporally coordinates 
membrane remodeling and actin-dependent release of endosomal tubules and buds, 
which is required for stage I melanosome homeostasis and PMEL fibril formation. 
 
 
 
Discussion 
Our data show that the formation of PMEL amyloid fibrils and melanosome identity 
rely on tight regulation of the homeostasis of stage I melanosomes and their 
transient interaction with lysosomes. By controlling membrane remodeling at stage I 
melanosomes, PIKfyve activity balances the import of lysosomal proteases and the 
steady state level of their substrate, PMEL, and thereby regulates the formation of 
amyloid matrix and the preservation of melanosome identity (Figure 7). Functionally, 
PIKfyve activity regulates morphology, size and number of stage I melanosomes by 
promoting the formation of membrane tubules and buds that are released in a 
mechanism involving branched endosomal actin dynamics (Figure 7 inset). Inhibition 
of PIKfyve activity abrogates membrane remodeling, causing an imbalance favouring 
stage I melanosomes homotypic fusion over fission that reduces the number and 
increases the size of stage I melanosomes. The imbalance between homotypic 
fusion and fission causes accumulation of PMEL that saturates amyloidogenic 
processing and sorting machineries. These defects result in accumulation and 
aberrant aggregation of amyloidogenic PMEL fragments impairing fibril formation.  
 
Interorganelle interactions ensure PMEL amyloid formation 
The data presented here confirm the requirement of lysosomal proteases for PMEL 
processing and amyloid formation, although their localization is separated from 
PMEL (Ho et al., 2016; Kawaguchi et al., 2015; Leonhardt et al., 2013; Raposo et al., 
2001). We describe a model in which transient kiss-and-run interactions and fusions 
between endolysosomes and PMEL-containing stage I melanosomes ensure PMEL 
processing by lysosomal proteases. These transient interactions provide a dynamic 
means to coordinate melanosome maturation with PMEL processing and fibril 
formation and thus ensure proper amyloid assembly. The kiss-and-run interactions 
that we describe do not lead to full fusion of both compartments and are thus 
consistent with previous observations that endolysosomes and melanosomes co-
exist as distinct, but proximate organelles in melanocytes (Raposo et al., 2001). By 
regulating interorganelles interaction, the PIKfyve activy appears as a key element of 
the acquisition of melanosome identity. 
Inhibition of PIKfyve activity results in longer interorganelle contacts, which 
correlates with mislocalization of endolysosomal proteins to melanosomes. Such 
impaired segregation of melanosomal and lysosomal cargo was suggested to affect 
	PMEL fibril formation and early melanogenesis (Giordano et al., 2009). One can 
imagine that the increased lysosomal character of maturing melanosomes may affect 
PMEL assembly rates.  
 
PIKfyve activity promotes membrane remodeling 
Our data demonstrate that PIKfyve activity promotes membrane remodeling and 
tubule formation required to maintain stage I melanosome number, homeostasis and 
function in melanocytes. The molecular mechanism by which PIKfyve activity 
induces the formation of membrane tubules in mammalian cells still remains elusive. 
PI(3,5)P2 produced by PIKfyve activates transient receptor potential mucolipin 
(TRPML) channel family and mice carrying a mutation in TRPML3, which is highly 
expressed in melanocytes, show pigmentation abnormalities (Di Palma et al., 2002; 
Dong et al., 2010). Activation of the TRPML protein family by the small molecule 
activator MLSA1 was shown to rescue the enlarged compartment phenotype of 
PI(3,5)P2-depleted FIG4 and VAC14 knockout cells (Dong et al., 2010; Zou et al., 
2015). However, in melanocytes MLSA1 co-treatment with YM201636 neither 
counteracted stage I melanosome enlargement nor rescued membrane tubule 
formation (Figure S4A-B). These findings indicate that during melanosome 
biogenesis, TRPMLs may not be downstream effectors of PIKfyve activity, which is 
in line with our observations in HeLa cells (Bissig et al., 2017). It is worth noting that 
mice mutant for TRPML3,VAC14 and FIG4 exhibit different fur pigmentation 
phenotypes (Atiba-Davies and Noben-Trauth, 2007; Chow et al., 2007; Jin et al., 
2008; Zhang et al., 2007), which may reflect distinct molecular roles.  PI(3,5)P2 was 
also shown to activate melanosomal two-pore sodium channel 2 (TPC2) that 
negatively regulates pigmentation (Bellono et al., 2016). However, TPC2 acts mainly 
on pigmented melanosomes, whereas PIKfyve activity is involved in homeostasis of 
unpigmented melanosomes and inhibition of PIKfyve activity does not impair melanin 
production.  
It is attractive to speculate that PI(3,5)P2 synthesis by PIKfyve triggers the 
recruitment of PI(3,5)P2-binding effector proteins, which may have membrane 
bending properties, as shown for the BAR domain of SNX1 involved in retrograde 
transport (Carlton et al., 2004). Recently, the PROPPIN domain of yeast Atg18, 
which binds PI(3)P and PI(3,5)P2, was shown to drive membrane tubule formation 
and fission via bilayer insertion of an amphipathic alpha-helix and oligomerization 
	(Gopaldass et al., 2017). This membrane deformation and fission function may be 
shared by other PROPPINs, such as the mammalian WIPI proteins, which also 
contain potential amphipathic alpha-helical features. Interestingly, mammalian WIPI1 
is involved in early melanogenesis and is thus a promising PI(3,5)P2 effector in 
melanocytes (Ho et al., 2011).  
Our data further provide evidence that membrane tubules generated by PIKfyve 
activity are released by a mechanism involving branched actin dynamics. As 
PI(3,5)P2 regulates endosomal branched actin, it is likely that PIKfyve activity also 
controls actin-dependent membrane release. A role of actin in membrane release is 
exemplified by the fission of Shiga-toxin carriers induced by actin-driven lipid phase 
separation (Allain et al., 2004; Romer et al., 2010; Roux et al., 2005) and in 
endosomal fission associated to ER contact sites (Rowland et al., 2014). The actin 
network may also promote membrane reorganization and neck constriction by 
inducing mechanical forces, which may involve the action of actin-based motors 
(Derivery et al., 2009; Ripoll et al., 2018). In that respect it is interesting to note that 
overexpression of myosin 1b affects early endosome morphology, slows PMEL 
processing and impairs PMEL fibril formation (Salas-Cortes et al., 2005) – 
phenotypes reminiscent of PIKfyve inhibition. 
 
PIKfyve mediated membrane remodeling is required for formation of PMEL 
amyloid matrix  
Our study provides evidence that formation of early melanosomal membrane tubules 
initiated by PIKfyve activity is co-ordinated with PMEL amyloid assembly and 
melanosome maturation. Similarly, endosome maturation was described to be co-
ordinated with endosome tubule formation (van Weering et al., 2012), indicating that 
melanocytes have fine-tuned a ubiquitous endosomal process for melanosome 
biogenesis. Membrane tubules formed during endosome maturation serve cargo 
sorting to different cellular locations, which is ensured by the assembly of various 
sorting machineries. In melanocytes, tubules emerging in an actin dependent 
manner from recycling endosomes transport melanogenic enzymes, transporters 
and accessory proteins to melanosomes for pigment synthesis (Delevoye et al., 
2016; Dennis et al., 2016; Setty et al., 2007; Sitaram et al., 2012). These tubules are, 
however, distinct from the PIKfyve-driven tubules described here, as we do not 
observe any defect in pigment synthesis. Endosomal tubules formed by PIKfyve 
	activity are involved in endosome-to-TGN retrograde transport (de Lartigue et al., 
2009; Rutherford et al., 2006), a process that also involves endosomal actin network 
(Seaman et al., 2013). However, such retrograde transport has not been described 
for PMEL. The membrane remodeling initiated by the PIKfyve activity contributes 
here to homotypic fusion-fission processes that allow a homogenous repartition of 
PMEL within the small and highly dynamic population of stage I melanosomes. 
Impaired membrane remodeling results then in the accumulation of PMEL lumenal 
fragments in enlarged, immotile and fewer stage I melanosomes. This accumulation 
saturates PMEL processing and sorting machinery and leads to aberrant 
aggregation of PMEL and thus a defect in PMEL fibril formation and melanosome 
maturation. Interestingly, evidence suggests that terminal proteolytic maturation of 
lumenal PMEL fragments only occurs after aggregation into a pre-matrix (Leonhardt 
et al., 2013). Thus, impaired pre-matrix assembly may lead to accumulation of 
partially processed lumenal PMEL fragments that aberrantly aggregate due their 
amyloidogenic nature. 
 
Implications for pathological amyloid formation 
The PMEL fibrils that assemble within melanosomes are amyloids (Fowler et al., 
2006). In contrast to pathological amyloids that are associated with 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s or Huntington’s 
disease, PMEL amyloid fibrils are not pathogenic and serve beneficial functions. 
They are thus called functional or physiological amyloids. Nevertheless, the 
amyloidogenic nature of PMEL presents a potential danger for the cell, as aberrant 
aggregation may be toxic (Watt et al., 2011). It is possible that long-term inhibition of 
PIKfyve activity may damage melanosome integrity by accumulation of toxic PMEL 
aggregates and/or melanin intermediates, perhaps leading to melanocyte death. 
Interestingly, mice uniquely knockout for PIKfyve in pigment cells (Liggins et al., 
2018) exhibit hair greying that is similar to mouse models with impaired PMEL fibril 
(Rochin et al., 2013) and their melanocytes display vacuolar compartments that are 
reminiscent of our observations. Lower melanocyte survival rates may also explain 
why VAC14 and FIG4 mutant mice show hypopigmentation phenotypes, while we 
did not observe impaired pigment synthesis. Since PMEL fibrils sequester melanin 
and thus might facilitate melanin transfer to keratinocytes, fur hypopigmentation may 
also result from inefficient pigment transfer. These two models are not mutually 
	exclusive.  
In view of the interesting similarities between intracellular trafficking and processing 
of PMEL and amyloid precursor protein (APP), which is involved in Alzheimer’s 
disease (Bissig et al., 2016; Sannerud et al., 2016), our studies may also have 
important implications for pathological amyloid formation during Alzheimer’s disease. 
Intriguingly, PIKfyve depletion leads to massive neurodegeneration in individuals 
with mutations of FIG4 and VAC14 (Baulac et al., 2014; Campeau et al., 2013; Chow 
et al., 2007; Lenk et al., 2011; Lenk et al., 2016) and PIKfyve influences  APP 
(Balklava et al., 2015; Currinn et al., 2016). It is therefore tempting to speculate that, 
in neurons, PIKfyve activity regulates the abundance of an amyloidogenic substrate 
and its proteases in a compartment known to generate the Abeta intracellular pool 
(Peric and Annaert, 2015; Rajendran and Annaert, 2012; Sannerud et al., 2016). 
Further work will determine whether PIKfyve activity plays analogous roles in 
physiological and pathological amyloid formation.  
 
Materials and Methods  
 
Cell culture, transfections and drug treatment 
Human melanocytic MNT-1 cells and primary melanocytes were maintained as 
previously described (Berson et al., 2001; Raposo et al., 2001; van Niel et al., 2015). 
Cells were transfected according to manufacturer’s recommendation with DNA and 
siRNA using JetPrime (Polyplus transfection TM) and oligofectamine (Invitrogen), 
respectively. Experiments were performed 16h after transfection with DNA. siRNA 
transfections were performed twice at 48h interval and experiments were performed 
96h after the first siRNA transfection. If not otherwise indicated, cells were incubated 
for 2h with 1.6 µM YM201636 (Abcam), 200 µM CK-666 (Tocris), 1µM Vps34 
inhibitor (IN1, Calbiochem) or DMSO (Sigma-Aldrich). YM201636 was washed out 
for 1h to 4h at 37°C after 3 washes with cold medium. If indicated 200 µM CK-666 
(Tocris) was present during the washout. 
 
Reagents, antibodies, siRNAs and plasmids 
Reagents were obtained from the following sources: DAPI (4’,6-diamidino-2-
phenylindole), Dextran 10’000 MW conjugated to Alexa Fluor 488, 555 or 647 and 
DQ-BSA from Thermo Fisher Scientific; YM201636 from Abcam; MagicRed probe 
from Immuno Chemistry Technologies; CK-666 from Tocris; IN1 from Calbiochem; 
pepstatinA and E-64d from Calbiochem; leupeptin from Euromedex and other 
reagents were obtained from Sigma-Aldrich.  
Antibodies were obtained from the following sources: anti-FIG4 (ab186269), anti-
VAC14 (ab67369), anti-Melanoma (HMB45) (ab787), anti-ß-TUB (ab6046), anti-
PSEN2 (ab51249), anti-TYRP1 (ab3312), anti-EEA1 (Ab70521) antibodies and 
horseradish peroxidase (HRP)-conjugated goat polyclonal antibodies to rabbit IgG 
(ab6721) and to mouse IgG (ab6789) from Abcam; anti- PMEL NKI from 
Neomarkers, anti-PIKfyve antibody (PCR-PIKFYVE-3C9) from Developmental 
Studies Hybridoma Bank (DSHB); mouse anti-LAMP1 antibody (555798) from BD 
Biosciences; secondary goat anti-rabbit or anti-mouse antibodies conjugated to Alex 
Fluor 488, 555 or 647 were from Thermo Fisher Scientific. Protein A conjugated to 
15 nm gold particles (PAG15) and BSA conjugated to 5 nm gold particles (BSA-gold 
5nm) were from Cell Microscopy Center (AZU, Utrecht University, Netherlands); 
Affinity-purified anti-peptide antibodies recognizing the PMEL N-terminus (anti-
	PMEL-N) (Berson et al., 2003) and C-terminus (anti-PMEL-C) (Raposo et al., 2001) 
were described previously. 
The siRNAs targeting FIG4 (L019141), VAC14 (L015729), PIKfyve (L005058) and 
non-targeting control (D001810) ON-TARGET plus SMARTpool were from Thermo 
Fisher Scientific. 
The 2xFYVE-GFP (Gillooly et al., 2000) and LAMP1-mRuby2 (Lam et al., 2012) 
(Addgene plasmid #55902) plasmid were kind gifts from Harald Stenmark and 
Michael Davidson, respectively. 
 
Dextran internalization assays  
Dextran internalization for Dextran transfer experiments: To internalize Dextran 
10’000MW AF555 into endolysosomes, MNT-1 cells were pulsed with 1mg/ml 
Dextran-AF555 at 37°C for 4h, washed 3 times with cold medium and chased with 
conjugate-free medium for 20h at 37°C (Bright et al., 2005).  
Dextran-AF647 co-internalization with DQ-BSA: MNT-1 cells were pretreated for 2h 
with 1.6µM YM201636 or DMSO. Then Dextran-AF647 and DQ-BSA were co-
internalized at a concentration of 50µg/ml each for 2h at 37°C. Cells were washed 3 
times with cold medium and incubated for 1h with conjugate-free medium at 37°C. 
Snapshots of live-cells were taken at 37°C in imaging buffer (20mM Hepes-NaOH 
pH 7.4 140mM NaCl, 2.5mM KCl, 1.8mM CaCl2, 1.0mM MgCl2, 4.5g/L D-Glucose). 
YM201636 or DMSO was present throughout the experiment.  
 
Electron microscopy 
For conventional EM, MNT-1 were grown on coverslips, fixed in 2.5% glutaraldehyde 
in 0.1 M cacodylate buffer for 24 h, post-fixed with 1% osmium tetroxide, dehydrated 
in ethanol and embedded in epon as described (Raposo et al., 2001). For EM 
analysis of RPE sections, tissues from newborn mice were processed as previsouly 
(Rochin et al., 2013) For high-pressure freezing MNT-1 cells were grown on 
carbonated sapphire discs (30 mm in diameter) and high-pressure frozen using a 
HPM 100 (Leica Microsystems) or HPM Light µ (CryoCapCell) in FBS serving as 
filler. High-pressure frozen samples were transferred to an AFS (Leica 
Microsystems) with precooled (-90°C) anhydrous acetone containing 2% osmium 
tetroxide and 1% H2O. Freeze substitution and epon embedding was performed as 
described (Hurbain et al., 2008). Ultrathin sections of cell monolayers or RPE were 
	prepared with a Reichert UltracutS ultramicrotome (Leica Microsystems) and 
contrasted with uranyl acetate and lead citrate.  
For ultrathin cryosectioning and immunogold labeling, cells were fixed in 2% PFA, 
0.2% glutaraldehyde in 0.1M phosphate buffer pH 7.4. Cells were processed for 
ultracryomicrotomy and immunogold labeled using PAG 15 as described (Raposo et 
al., 2001). 
All samples were examined with a FEI Tecnai Spirit electron microscope ( Thermo 
Fisher Scientific), and digital acquisitions were made with a numeric camera 
(Quemesa; EMSIS).   
 
Live cell microscopy and immunofluorescence analysis 
MNT-1 cells grown on coverslips were fixed with 2% PFA, permeabilized with 0.05% 
saponin/1% BSA in PBS, quenched with 50mM glycine and processed for indirect 
immunolabeling. Images were captured on a LSM 780 confocal microscope (Zeiss) 
using an oil-immersion plan Apo 63x A/1.40 NA objective lens.  
Live-cell imaging experiments were done in fluorodishes (World Precision 
Instruments) at an inverted spinning disc microscope (Nikon) using an oil-immersion 
plan Apo 100x A/1.40 NA objective lens. Live-cell imaging was performed at 37°C in 
imaging buffer (20mM Hepes-NaOH pH 7.4 140mM NaCl, 2.5mM KCl, 1.8mM 
CaCl2, 1.0mM MgCl2, 4.5g/L D-Glucose) and movies were taken at 0.4s frame rate 
for 2min. Data were collected using Metamorph Software and analyzed using 
ImageJ, Icy and CellProfiler software.  
 
Image analysis and quantification 
Melanosome stages were defined by morphology (Raposo et al., 2001; Seiji et al., 
1963). Length and width of melanosomes, as well as the size were measured using 
ImageJ software. To measure contact times, organelles were segmented using Icy 
software and the time that two organelles partially overlap was assessed. The size of 
organelles was measured after segmentation using Icy software. Colocalization was 
quantified using CellProfiler software calculating the correlation coefficient. Dextran 
transfer to 2xFYVE-GFP compartments (defined as ROI) was quantified measuring 
the fluorescence intensity of the Dextran channel in the ROI using ImageJ. P values 
were determined by Student’s t-test, unpaired, unequal variance (*p<0.05, **p<0.01, 
***p<0.001). 
	 
Other methods 
Western blot: 
For Western blots a Triton X-soluble lysate was prepared in 20 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1% TX-100, 1 mM EDTA, protease inhibitors. The Triton X-insoluble 
fraction was resuspended in 1% SDS, 1% B-mercaptoethanol in PBS containing 
protease inhibitors, incubated for 10 min at RT and then heated for 10 min at 100°C.  
Membrane-cytosol fractionation 
Cells are scraped and centrifuged at 900 rpm for 5min at 4°C. The pellet is 
homogenized in homogenization buffer (0.25M sucrose, 10mM Hepes-NaOH pH 7,4) 
and then centrifuged at 2000 rpm for 10min at 4°C. The pellet is resuspended in the 
homogenization buffer and after centrifugation at 2000 rpm for 10min, the Post 
Nuclear Supernatant (PNS) is collected and centrifuged at 53000 rpm for 1h at 4°C. 
The supernatant (cytosol fraction) is collected and the pellet (membrane fraction) is 
resuspended in (10mM Tris-HCL pH7.4, 150mM NaCl, 0.5mM EDTA) solution 
containing protease inhibitors. 
Melanin assay:  
Cells were disrupted by sonication in 50 mM Tris-HCl, pH 7.4, 2 mM EDTA, 150 mM 
NaCl, 1 mM DTT, and protease inhibitors. Pigment was pelleted at 16000g for 15min 
at 4°C, rinsed once in ethanol/ether (1:1), and dissolved in 2M NaOH/20% DMSO at 
60°C. Melanin content was measured as optical density at 492nm.   
Ratiometric pH measurement:  
pH-sensitive fluorophore Oregon green 488 (DextranOG) and pH-insensitive 
fluorophore Alexa Fluor 647 (DextranAF647) were internalized and imaged as 
described above in Dextran internalization assays. To convert fluorescence values to 
pH the emission of the two dyes was recorded separately and the fluorescence ratio 
was converted to pH using an internal calibration curve. To acquire the calibration 
curve cells were sequentially bathed for 5min in 143mM KCl, 5mM glucose, 1mM 
MgCl2, 1mM CaCl2, 20mM Hepes buffered to a pH ranging from 4.0 to 7.5 and 
containing 10µM nigericin and 5µM monensin. 
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Figure 1. Interference with the PIKfyve complex affects melanosome 
morphology and identity  
A-B) EM analysis of epon-embedded RPE of newborn Vac14+/+ and Vac14-/- mice 
(A) and Fig4+/+ and Fig4-/- mice (B). (Scale bar: 2µm). C-E) Quantification of 
melanosome number per µm2 RPE (C), melanosome size (D) and the ratio (R) of 
maximal width and length of melanosomes (E). F) MNT-1 cells were treated with 
control siRNAs or siRNAs against VAC14, FIG4 and PIKfyve and knock-down 
efficiencies were analyzed by immunoblotting. Antibodies to tubulin (anti-TUB) were 
used as equal loading marker. G) MNT-1 cells treated with siRNAs as in F were 
fixed, permeabilized and immuno-labelled using anti-LAMP1 (red) and anti-PMEL-
NKI antibodies (green). DAPI was used to stain nuclei. Insets show magnifications of 
the boxed regions. (Scale bars: 10 µm). H) Quantification of colocalization between 
LAMP1 and PMEL fluorescence. I) MNT-1 cells treated with control siRNAs or 
siRNAs against VAC14, FIG4 or PIKfyve were fixed, permeabilized and immuno-
labeled using anti-TYRP1 antibody (green) and DAPI (blue) to stain nuclei. 
Pigmented melanosomes are shown in bright field images. Panels on the right show 
magnifications of the boxed regions. (Scale bars: 10 µm). J) Quantification of melanin 
content of MNT-1 cells treated with control siRNAs or siRNAs against VAC14, FIG4 
or PIKfyve. K) MNT-1 cells treated with control siRNAs or siRNAs against VAC14, 
FIG4 or PIKfyve were fixed, permeabilized and immuno-labeled using DAPI (blue) to 
stain nuclei and anti-PMEL (HMB45) antibody (grey) that recognizes PMEL fibrils. 
(Scale bars: 10 µm). L) Quantification of the mean fluorescence intensity per cell 
normalized to siCTRL. Data are represented as mean ± SEM. (See also Figure S1) 
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Figure 2. M-alpha fragments accumulate upon interference with PIKfyve 
function or lysosomal protease activity 
A) Schematic representation of PMEL maturation and proteolytic processing and 
sorting. PMEL protein domains: signal peptide (SP), N-terminal region (NTR), 
polycystic kidney disease protein-1-like repeat domain (PKD), repeat domain (RPT), 
kringle-like domain (KDL), C-terminal fragment (CTF), intracellular domain (ICD). 
PMEL processing proteases are indicated in red: proprotein convertase (PC), beta-
site APP-cleaving enzyme 2 (BACE2) and presenilin 2 (PSEN2). Colored 
background highlights the intracellular localization of the different PMEL cleavage 
forms. B) Table of antibodies used in this study summarizing their epitopes and the 
major PMEL forms they recognize. C-F) MNT-1 cells were treated for 2 h or 24 h with 
1.6 µM YM201636 (C-D) or with a mixture of protease inhibitors (100 µM leupeptin, 
10 µM pepstatin A and 10 µM E-64d) (E-F) and Triton X-100-soluble (C and E) and 
Triton X-100-insoluble (D and F) lysates were analyzed by immuno-blotting using 
antibodies against the PMEL C-terminus (anti-PMEL-C), the PMEL N-terminus (anti-
PMEL-N), the PMEL RPT domain (anti-PMEL-HMB45), the PMEL PKD domain (anti-
PMEL-I51) and Tubulin (anti-TUB) as equal loading marker. The different PMEL 
fragments are annotated on the right. Stars indicate M-alpha fragments derived from 
another isoform generated by alternative splicing. Right panels show higher 
exposures. Data are represented as mean ± SEM. (See also Figure S1) 
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Figure 3. Stage I melanosomes and endolysosomes transiently interact and 
exchange content even upon inhibition of PIKfyve activity A) MNT-1 cells treated 
for 2 h with 1.6 µm YM201636 or DMSO were fixed, permeabilized and immuno-
labelled using DAPI (blue) to stain nuclei and anti-PMEL-N (green) and anti-LAMP1 
(red) antibodies to label mature PMEL/M-alpha and endolysosomes, respectively. 
Panels on the right show magnifications of the boxed regions. (Scale bars: 10 µm). 
B-D) Quantification of the mean fluorescence intensity (FI) of anti-PMEL-N signal in 
LAMP1 compartments (B), of the number of LAMP1 compartments per cell (C) and of 
the size of LAMP1 compartments (D). E) MNT-1 cells treated for 2 h with 1.6 µM 
YM201636 or DMSO were fixed, permeabilized and immuno-labelled using DAPI 
(blue) to stain nuclei and anti-PMEL-N (green) and anti-EEA1 (red) antibodies to 
label mature PMEL/M-alpha and stage I melanosomes, respectively. Panels on the 
right show magnifications of the boxed regions. (Scale bars: 10 µm). F-H) 
Quantification of the mean fluorescence intensity (FI) of anti-PMEL-N signal in EEA1 
compartments F), of the number of EEA1 compartments per cell G) and of the size of 
EEA1 compartments H). I-J) MNT-1 cells were co-transfected with LAMP1-mRuby2 
(red) and 2xFYVE-GFP (green), to mark endolysosomes and stage I melanosomes, 
respectively. Then cells were treated for 2 h with DMSO (I) or 1.6 µM YM201636 J) 
and subsequently YM201636 was washed out for 1 h (Figure S3H). Movies were 
taken at a frame rate of 0.4 s by spinning disc microscopy. The left panels show the 
first frame of the movies. The right panels show stills of the magnified regions. (Scale 
bars: 10 µm).J) Quantification of the mean duration time of interaction. L-N) Dextran-
AF555 (Dex555) (red) was internalized by 4 h pulse and 20 h chase into lysosomes 
of MNT-1 cells overexpressing 2xFYVE-GFP (localized on stage I melanosomes). 
Then cells were treated for 2 h with DMSO (L) or 1.6 µM YM201636 (N) and movies 
were taken at a frame rate of 0.4 s by spinning disc microscopy. Upper panels show 
stills of a movie, where lyososomal DextranAF555 is shown in red and 2xFYVE-GFP 
localized on stage I melanosomes in green. Lower panels illustrate DextranAF555 
transfer from lysosomes to 2xFYVE-GFP compartments. In these panels only 
lysosomal DextranAF555 is shown in grey and circles indicate the positions of the 
2xFYVE-GFP compartment. M-O) Fluorescence intensity of lysosomal 
DextranAF555 in 2xFYVE-GFP compartments denoted with circles in L and N in cells 
treated with DMSO (M) and YM201636 (O). Data are represented as mean ± SEM. 
(See also Figure S3)  
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Figure 4. PMEL fragments accumulate in enlarged EEA1 compartments  
A-B) EM analysis of epon-embedded MNT-1 cells treated for 2 h with the PIKfyve 
inhibitor YM201636 (A) or knocked-down for VAC14, FIG4 and PIKfyve (B). Upper 
panels show low magnification overviews of unpigmented and pigmented 
melanosomes and lower panels show unpigmented melanosomes at higher 
magnification. Arrowheads point towards enlarged stage I melanosomes and arrows 
highlight aberrant unpigmented melanosomes containing unstructured aggregates 
present in VAC14, FIG4 and PIKfyve knock-down cells. (Scale bars: upper panels 
500 nm and lower panels 200 nm). C) Quantification of stage I melanosome size. D) 
Quantification of unpigmented melanosomes grouped into stage I, stage II and 
aberrant melanosomes. E) Quantification of pigmented and unpigmented 
melanosomes expressed as a percentage of the total number of melanosomes. F) 
EM analysis of epon-embedded human primary melanocytes treated with control 
siRNAs or siRNAs against VAC14, FIG4 and PIKfyve. Right panels show 
magnifications of stage I melanosomes. (Scale bars: left panels 1 µm and right 
panels 500 nm). G) Ultrathin cryosections of MNT-1 cells treated for 2 h with 1.6 µM 
YM201636 or DMSO were immunogold labelled using anti-PMEL-N antibody 
followed by protein-A gold 15 nm diameter. Arrows indicate clathrin coats. (Scale 
bars: 200nm). H) Quantification of the percentage of gold particles on ILVs 
expressed as a percentage of the total number of gold particles. I) Quantification of 
the number of gold particles on ILVs per compartment. Data are represented as 
mean ± SEM. 
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Figure 5. PIKfyve activity promotes formation of membrane tubules that 
modulate PMEL accumulation.  
A) Snapshots of live 2xFYVE-GFP transfected MNT-1 cells treated for 2 h with 1.6 
µM YM201636 or DMSO. Magnifications of the boxed regions illustrate the absence 
of membrane tubules in PIKfyve inhibitor treated cells. (Scale bars: 10 µm). B-D) 
Quantification of 2xFYVE-GFP tubules per cell (B), of 2xFYVE-GFP compartments 
size (C) and number per cell (D). E) EM analysis of HPF/freeze substituted MNT-1 
cells treated for 2 h with DMSO or 1.6 µM YM201636 and subsequently YM201636 
was washed out for 4 h. Arrows point at membrane tubules and deformations. (Scale 
bars: 500 nm). F) Examples of compartments undergoing membrane remodeling 
upon 4h of YM201636 washout. (Scale bars: 200 nm). G-H) Quantification of the 
percentage of tubulated stage I melanosomes G) and of stage I melanosome size H). 
Data are represented as mean ± SEM. I) MNT-1 cells treated as indicated were fixed, 
permeabilized and immuno-labelled using DAPI (blue) to stain nuclei and anti-PMEL-
N (green) and anti-EEA1 (red) antibodies to label the PMEL/M-alpha and stage I 
melanosomes, respectively. Panels on the right show magnifications of the boxed 
regions. (Scale bars: 10 µm). J-K) Quantification of EEA1 size (J) and the mean 
fluorescence (Fl) of PMELN in EEA1 compartment (K). Data are represented as 
mean ± SEM.  
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Figure 6. Endosomal actin dynamics is required for membrane tubule release 
A) MNT-1 cells treated for 2 h with DMSO or 1.6 µM YM201636 in the presence or 
absence of 200 µM CK-666 were fixed, permeabilized and immuno-labelled using 
anti-EEA1 antibody (green) and phalloidin-TRITC (red) to label actin. Lower panels 
show magnifications of the boxed regions. B) Snapshots of live 2xFYVE-GFP 
expressing MNT-1 cells treated for 2 h with DMSO or 200 µM CK-666 and after 
washout of YM201636 in the absence and presence of 200 µM CK-666. Arrows 
highlight membrane tubules or buds. Magnifications of boxed regions illustrate 
membrane tubules. C) Stills of compartments of cells in B illustrating membrane 
tubules and release. White arrows highlight membrane tubules or buds. Green and 
red arrows highlight membrane bud release and retraction, respectively. D-E) 
Quantification of tubules per cell (D) and of the percentage of tubules undergoing 
release (E). F) EM analysis of HPF/freeze substituted MNT-1 cells treated for 2 h 200 
µM CK-666 or 1.6 µM YM201636, which was subsequently washed out for 1 h and 4 
h in the presence of 200 µM CK-666. Arrows point at membrane tubules and 
deformations. (Scale bars: 200 nm). G) MNT-1 cells treated as indicated were fixed, 
permeabilized and immuno-labelled using DAPI (blue) to stain nuclei and anti-PMEL-
N (green) and anti-EEA1 (red) antibodies to label the PMEL/M-alpha and stage I 
melanosomes, respectively. Panels on the right show magnifications of the boxed 
regions. (Scale bars: 10 µm). H-I) Quantification of EEA1 size (H) and the mean 
fluorescence (Fl) of PMELN in EEA1 compartment (I). Data are represented as mean 
± SEM.  
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Figure 7. Working model of PIKfyve function in melanosome biogenesis 
Stage I melanosomes are highly dynamic organelles undergoing frequent homotypic 
fusion and fission. In these compartments PMEL fibril formation is initiated by PMEL 
processing and sorting to ILVs. PMEL is processed by lysosomal proteases that are 
delivered to stage I melanosomes via transient interorganelle interactions. PI(3,5)P2 
synthesized by PIKfyve regulates morphology, size and number of stage I 
melanosomes by promoting formation of membrane tubules and buds that are 
released in a mechanism involving branched endosomal actin dynamics. Inhibition of 
PIKfyve activity abrogates membrane remodeling, reduces the number and increases 
the size of stage I melanosomes leading to accumulation and unstructured 
aggregation of PMEL thus impairing fibril formation and melanosome maturation. 
PIKfyve inhibition also prolongs interactions between stage I melanosomes and 
lysosomes, probably because PIKfyve activity and PI(3,5)P2 are also involved in 
membrane remodeling processes that lead to segregation of the two compartments. 
Prolonged interorganelle interactions most likely cause mislocalization of 
endolysosomal proteins to melanosomes and a loss of melanosomal identity during 
the whole melanogenesis process. Inset: schematic representation of the role of 
PIKfyve activity on the regulation of import/export processes in stage I  
melanosomes.  
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